Towards the use of localised delivery strategies to counteract cancer therapy–induced cardiotoxicities
Name
13346_2020_885_ReferencePDF.pdf
Size
1.57 MB
Format
Unknown
Checksum (MD5)
edfd0677dcffab58a373007933569e48
Author(s)
Monahan, David S.
Almas, Talal
Wyile, Robert
Cheema, Faisal H.
Duffy, Garry P.
Hameed, Aamir
Date Issued
January 2021
Journal
Drug Delivery and Translational Research
Publisher
Springer US
Version
Author's final manuscript
Abstract
Abstract
Cancer therapies have significantly improved cancer survival; however, these therapies can often result in undesired side effects to off target organs. Cardiac disease ranging from mild hypertension to heart failure can occur as a result of cancer therapies. This can warrant the discontinuation of cancer treatment in patients which can be detrimental, especially when the treatment is effective. There is an urgent need to mitigate cardiac disease that occurs as a result of cancer therapy. Delivery strategies such as the use of nanoparticles, hydrogels, and medical devices can be used to localise the treatment to the tumour and prevent off target side effects. This review summarises the advancements in localised delivery of anti-cancer therapies to tumours. It also examines the localised delivery of cardioprotectants to the heart for patients with systemic disease such as leukaemia where localised tumour delivery might not be an option.
Graphical abstract
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s13346-020-00885-3
